Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.06−0.03 (-2.75%)
Close on Nov 18, 2026Market cap $282.13MP/E –Yield –
Autolus Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Autolus Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$247.44M. For fiscal 2025 it was -$270.54M. The highest annual figure on record is -$23.42M in fiscal 2017.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$270.54M | – |
| FY2024 | Dec 31, 2024 | -$241.43M | – |
| FY2023 | Dec 31, 2023 | -$179.70M | – |
| FY2022 | Dec 31, 2022 | -$143.41M | – |
| FY2021 | Dec 31, 2021 | -$141.05M | – |
| FY2020 | Dec 31, 2020 | -$168.15M | – |
| FY2018 | Sep 30, 2018 | -$57.53M | – |
| FY2017 | Sep 30, 2017 | -$23.42M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$43.84M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$59.51M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$72.47M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$71.62M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$61.22M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$65.24M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$75.86M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$67.88M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$58.93M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$38.76M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$53.27M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$42.91M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$44.38M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$39.15M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$11.65M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$37.35M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$39.06M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$36.19M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$39.87M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$47.33M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$42.71M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$39.54M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$38.56M | – |
See a number that looks wrong?